908106-07-0

Basic information

• Product Name: 9-(4-bromobenzyl)-9H-carbazole-3-carbaldehyde
• Synonyms: 9-(4-bromobenzyl)-9H-carbazole-3-carbaldehyde
• CAS NO: 908106-07-0
• Molecular Weight: 364.241
• Mol File: 908106-07-0.mol

Chemical Properties

• CAS DataBase Reference: 9-(4-bromobenzyl)-9H-carbazole-3-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 9-(4-bromobenzyl)-9H-carbazole-3-carbaldehyde(908106-07-0)
• EPA Substance Registry System: 9-(4-bromobenzyl)-9H-carbazole-3-carbaldehyde(908106-07-0)

Safety Data

• Hazardous Substances Data: 908106-07-0(Hazardous Substances Data)

Upstream product

• 1002318-81-1 9-(4-bromobenzyl)-9H-carbazole 
• 68-12-2 N,N-dimethyl-formamide 
• 86-74-8 9H-carbazole 
• 589-15-1 1-bromomethyl-4-bromobenzene 

Relevant articles and documents

Design, synthesis and evaluation of carbazole derivatives as potential antimicrobial agents

Five series of novel carbazole derivatives containing an aminoguanidine, dihydrotriazine, thiosemicarbazide, semicarbazide or isonicotinic moiety were designed, synthesised and evaluated for their antimicrobial activities. Most of the compounds exhibited potent inhibitory activities towards different bacterial strains (including one multidrug-resistant clinical isolate) and one fungal strain with minimum inhibitory concentrations (MICs) between 0.5 and 16 μg/ml. Compounds 8f and 9d showed the most potent inhibitory activities (MICs of 0.5–2 μg/ml). Furthermore, compounds 8b, 8d, 8f, 8k, 9b and 9e with antimicrobial activities were not cytotoxic to human gastric cancer cell lines (SGC-7901 and AGS) or a normal human liver cell line (L-02). Structure–activity relationship analyses and docking studies implicated the dihydrotriazine group in increasing the antimicrobial potency and reducing the toxicity of the carbazole compounds. In vitro enzyme activity assays suggested that compound 8f binding to dihydrofolate reductase might account for the antimicrobial effect.

Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors

In this study, a series of carbazole-rhodanine conjugates was synthesized and evaluated for their Topoisomerase II inhibition potency as well as cytotoxicity against a panel of four human cancer cell lines. Among these thirteen compounds, 3a, 3b, 3g, and

CARBAZOLE COMPOUND

The present invention provides a carbazole compound represented by formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R1 is a hydrogen atom, etc; R2 is a lower alkoxy group, etc; and R3 is a hydrogen atom, etc. The carbazole compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.